Oncotarget

Research Papers:

Primary tumor inflammation in gross tumor volume as a prognostic factor for nasopharyngeal carcinoma patients

Hao Peng, Lei Chen, Ling-Long Tang, Yuan Zhang, Wen-Fei Li, Yan-Ping Mao, Fan Zhang, Rui Guo, Li-Zhi Liu, Li Tian, Ai-Hua Lin, Ying Sun and Jun Ma _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:14963-14972. https://doi.org/10.18632/oncotarget.7699

Metrics: PDF 1968 views  |   HTML 1720 views  |   ?  


Abstract

Hao Peng1, Lei Chen1, Ling-Long Tang1, Yuan Zhang1, Wen-Fei Li1, Yan-Ping Mao1, Fan Zhang1, Rui Guo1, Li-Zhi Liu2, Li Tian2, Ai-Hua Lin3, Ying Sun1, Jun Ma1

1Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People’s Republic of China

2Imaging Diagnosis and Interventional Center, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People’s Republic of China

3Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-Sen University, Guangzhou, People’s Republic of China

Correspondence to:

Jun Ma, e-mail: [email protected]

Keywords: nasopharyngeal carcinoma, primary tumor inflammation, gross tumor volume, prognosis, intensity-modulated radiation therapy

Received: October 28, 2015     Accepted: January 31, 2016     Published: February 25, 2016

ABSTRACT

Purpose: The objective of this study is to investigate the prognostic value of primary tumor inflammation (PTI) in nasopharyngeal carcinoma (NPC) in the era of intensity-modulated radiation therapy (IMRT).

Results: PTI was observed in 376/1708 (22.0%) patients, and was present in the sphenoid sinus in 289/376 (76.9%), in the nasal cavity in 27 (7.2%), and in both places in 60 (15.9%). The estimated 4-year local relapse-free survival (LRFS), disease-free survival (DFS), overall survival (OS) and distant metastasis-free survival (DMFS) rates for PTI vs. non-PTI group were 89.2% vs. 96.1% (P < 0.001), 73.4% vs. 85.1% (P < 0.001), 85.0% vs. 92.1% (P < 0.001) and 83.6% vs. 91.4% (P < 0.001), respectively. After adjustment for these known prognostic factors, PTI was confirmed as an independent prognostic factor for LRFS (HR 2.152, 95% CI 1.318–3.516, P = 0.002), DFS (HR 1.581, 95% CI 1.204–2.077, P = 0.001) and DMFS (HR 1.682, 95% CI 1.177–2.402, P = 0.004).

Conclusions: Primary tumor inflammation was identified as a strong prognostic factor for patients with NPC in the era of IMRT and should be considered when devising future treatment strategies aimed at improving survival in NPC patients.

Materials and Methods: Data on 1708 patients with nonmetastatic, histologically-confirmed NPC treated with IMRT between November 2009 and February 2012 at Sun Yat-Sen University Cancer Center were retrospectively reviewed. Patient survival between PTI and non-PTI groups were compared.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7699